New research indicates that patients who come off popular weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who halt conventional lifestyle plans.
Research printed in a prominent health publication demonstrates that while obese individuals can lose substantial amounts of their body weight while undergoing treatment, the mass is regained at an estimated rate of 0.8 kg per month once they quit.
"Individuals buying these drugs need to be informed of the potential of quick weight regain when the medication is stopped," cautioned expert Dr. Susan Jebb.
This pace of regain suggests a return to pre-treatment weight in about 18 months.
Analyzing Approaches
The analysis, which reviewed 37 of studies involving over 9,000 of participants, compared the outcomes of GLP-1 agonists with other pills.
The team note that individuals who lose weight through diet and exercise typically see a less rapid weight regain—perhaps 0.1 kg a month—post-intervention.
Understanding the Rapid Rebound
Nutrition scientists suggest the mode of action of the drugs accounts for the amplified weight return.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Artificially providing the hormone levels several times higher than the body's typical production might result in the body to generate a reduced amount of its own natural hormone, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' leads to appetite is no longer kept in check, making excessive eating a significant risk."
A Lifelong Condition?
Medical guidelines recommend the jabs for people with weight-linked health risks, alongside recommended lifestyle changes.
Professionals say that, due to the high risk of weight regain, the therapy might need to be ongoing.
This opinion is supported by drug manufacturers, who note that the results "highlight the chronic nature of excess weight," similar to managing diseases like diabetes.
User Testimonies
Users who have stopped the jabs explain a intense return of appetite.
"It was like something that goes on and I was suddenly starving," described an individual.
This difficulty is compounded if users have not established lasting dietary or behavioural changes during therapy.
Growing Adoption
Survey data indicate that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is more common among women compared to men.
- The middle-aged demographic shows the highest usage rates.
- A large proportion access the medications through private prescriptions rather than public health services.
In conclusion, researchers emphasize that while these medications are powerful agents for weight loss, they are not a magic solution and maintained weight loss hinges on combined behavioural changes.
